Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4554194 | 0.89 | MAPT (0.59) | MAPTKMT2AHTTLMNAKCNN4 | |
| SCHEMBL29758021 | 0.77 | MAPT (0.57) | MAPTKMT2ACYP2C9DHODHSMN1; SMN2 | |
| SCHEMBL78396 | 0.74 | MAPT (0.48) | MAPTKMT2ACYP2C9DHODHSMN1; SMN2 | |
| SCHEMBL5046100 | 0.74 | KCNN4 (0.50) | MAPTKMT2AKCNN4 | |
| SCHEMBL22722985 | 0.74 | KCNN4 (0.50) | MAPTKMT2AKCNN4 | |
| SCHEMBL2517938 | 0.74 | KCNN4 (0.50) | MAPTKMT2AKCNN4 | |
| SCHEMBL2950212 | 0.72 | KCNN4 (0.50) | MAPTKMT2ACYP2C9SMN1; SMN2KIF11 | |
| SCHEMBL2950210 | 0.72 | KCNN4 (0.50) | MAPTKMT2ACYP2C9SMN1; SMN2KIF11 | |
| SCHEMBL10710486 | 0.72 | CES1 (0.48) | MAPTKMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL10989943 | 0.71 | MAPT (0.55) | MAPTKMT2AHTTLMNAKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | HAVCR2, ZC3HAV1, MAVS | MAPT 2483/4885KMT2A 2900/4885CYP2C9 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.